16:56 , Apr 19, 2019 |  BC Week In Review  |  Company News

Castle Creek gets U.S. rights to market Fibrocell's skin disease cell therapy

Castle Creek will pay $7.5 million up front for an exclusive license to commercialize Fibrocell's FCX-007 in the U.S. FCX-007 is a gene-modified autologous fibroblast that carries collagen type VII (COL7A1) to treat recessive dystrophic...
23:27 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Fibrocell reports Phase I/II data for FCX-007 in epidermolysis bullosa

In September, Fibrocell Science Inc. (NASDAQ:FCSC) reported interim data from a Phase I/II trial in 3 patients with recessive dystrophic epidermolysis bullosa (EB) showing that a single intradermal injection of FCX-007 led to >75% wound...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Financial News

Fibrocell completes private placement of convertible notes and warrants

Fibrocell Science Inc. (NASDAQ:FCSC), Exton, Pa.   Business: Gene/Cell therapy, Dermatology, Autoimmune   Date completed: 2016-09-08   Type: Private placement of convertible notes and warrants   Raised: $18.1 million   Shares outstanding prior: 43.9 million...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Company News

Fibrocell dermatology, autoimmune news

Fibrocell reduced headcount by 24 (about 50%) to about 24 and will wind down its azficel-T operations after the candidate missed the primary endpoint in a Phase II trial to treat vocal cord scarring. Fibrocell...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Clinical News

FCX-007: Phase I/II started

Fibrocell began an open-label Phase I/II trial to evaluate FCX-007 in about 12 patients. The Phase I portion will enroll about 6 adults and the Phase II portion will enroll 6 pediatric patients. Fibrocell and...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

FCX-007 regulatory update

Fibrocell said FDA requested an additional animal safety study in an IND for FCX-007 to treat recessive dystrophic epidermolysis bullosa (RDEB). FDA requested a toxicology-specific study in which FCX-007 is injected into non-grafted severe combined...
07:00 , Oct 5, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/2 cls Celgene Corp. (NASDAQ:CELG) JPMorgan Cory Kasimov Upgrade Overweight (from neutral) 7% $116.44 Kasimov upgraded on valuation after the...
23:46 , Sep 25, 2015 |  BC Extra  |  Company News

Fibrocell sinks after FDA requests more animal data

Fibrocell Science Inc. (NASDAQ:FCSC) fell $1.54 (24%) to $4.95 after it said FDA requested additional animal safety studies in an IND application for FCX-007 . The company said it expected to amend the IND with...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

Fibrocell, Intrexon preclinical data

In severe combined immunodeficiency (SCID) mice with human skin grafts, FCX-007 led to no adverse effects in 2- and 6-week toxicology studies. Additionally, Fibrocell said collagen type VII (COL7A1) expression from FCX-007 cells was confirmed...